International Access Strategy

We develop and implement HEOR strategies to ensure that the right evidence supporting your healthcare innovation meets the demands of payers, HTA organisations, policymakers, and other healthcare stakeholders.

We leverage state-of-the-art evidence synthesis techniques—network meta-analyses, population-adjusted indirect comparisons, external controls, validation of surrogate endpoints, and living evidence synthesis—to overcome gaps in the evidence base and to understand the value of your healthcare innovation.

We develop credible evidence-based health economic models to quantify the value and population health impact of your healthcare innovation: cost-effectiveness and budget impact models to support HTA submissions and payer discussions, generalised cost-effectiveness analyses incorporating novel elements of value, treatment sequence comparisons, and health equity impact evaluations with distributional cost-effectiveness analysis.

We quantify disease burden, treatment patterns, and treatment effects and assess patient, provider, and payer preferences using a wide range of existing RWE data sources and primary data collection.

Prior to any product launch, it is critical to understand the market environment you’re entering. Our market experts apply a structured approach to characterising the payer landscape, including the disease burden and unmet needs, current treatment practices, HTA and pricing information, competitive dynamics, and pipeline activity. We also specialise in stakeholder mapping, access and funding pathways, and analogue analyses.

We have a deep understanding of the evidence requirements and decision-making processes that govern the different health technology assessment (HTA) agencies around the globe. We help our customers in preparing for their HTA submissions—through a mix of early scientific advice, payer advisory boards, analogue analysis, and other forms of research.

We provide pricing strategies for our clients across the product life cycle, from early P&MA assessments through to global launch pricing and loss-of-exclusivity planning. We apply rigorous pricing research methodologies, coupled with sophisticated modelling techniques, to inform international price-referencing, launch-sequencing, and cross-indication pricing risks.

We are experts in developing payer value communication materials, including value propositions, objection handlers, FAQs, negotiation guides, and more. We pair our P&MA expertise with our digital and communications capabilities to craft positioning and messaging strategies that really resonate with payers.